Literature DB >> 33135059

A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?

Timo E Strandberg1,2, Peter Libby3, Petri T Kovanen4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33135059      PMCID： PMC8141298          DOI： 10.1093/ehjcvp/pvaa131

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  19 in total

Review 1.  Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications.

Authors:  Krishna G Aragam; Pradeep Natarajan
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

3.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

4.  Inflammatory and Cholesterol Risk in the FOURIER Trial.

Authors:  Erin A Bohula; Robert P Giugliano; Lawrence A Leiter; Subodh Verma; Jeong-Gun Park; Peter S Sever; Armando Lira Pineda; Narimon Honarpour; Huei Wang; Sabina A Murphy; Anthony Keech; Terje R Pedersen; Marc S Sabatine
Journal:  Circulation       Date:  2018-03-12       Impact factor: 29.690

5.  Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.

Authors:  Hillard Kaplan; Randall C Thompson; Benjamin C Trumble; L Samuel Wann; Adel H Allam; Bret Beheim; Bruno Frohlich; M Linda Sutherland; James D Sutherland; Jonathan Stieglitz; Daniel Eid Rodriguez; David E Michalik; Chris J Rowan; Guido P Lombardi; Ram Bedi; Angela R Garcia; James K Min; Jagat Narula; Caleb E Finch; Michael Gurven; Gregory S Thomas
Journal:  Lancet       Date:  2017-03-17       Impact factor: 79.321

6.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Authors:  Jean-Claude Tardif; Simon Kouz; David D Waters; Olivier F Bertrand; Rafael Diaz; Aldo P Maggioni; Fausto J Pinto; Reda Ibrahim; Habib Gamra; Ghassan S Kiwan; Colin Berry; José López-Sendón; Petr Ostadal; Wolfgang Koenig; Denis Angoulvant; Jean C Grégoire; Marc-André Lavoie; Marie-Pierre Dubé; David Rhainds; Mylène Provencher; Lucie Blondeau; Andreas Orfanos; Philippe L L'Allier; Marie-Claude Guertin; François Roubille
Journal:  N Engl J Med       Date:  2019-11-16       Impact factor: 91.245

7.  C-reactive protein levels and outcomes after statin therapy.

Authors:  Paul M Ridker; Christopher P Cannon; David Morrow; Nader Rifai; Lynda M Rose; Carolyn H McCabe; Marc A Pfeffer; Eugene Braunwald
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

8.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.

Authors:  Aruna D Pradhan; Aaron W Aday; Lynda M Rose; Paul M Ridker
Journal:  Circulation       Date:  2018-05-01       Impact factor: 29.690

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

10.  Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Peter Libby
Journal:  Eur Heart J       Date:  2020-06-14       Impact factor: 29.983
View more
  3 in total

Review 1.  Targeting inflammation in atherosclerosis - from experimental insights to the clinic.

Authors:  Oliver Soehnlein; Peter Libby
Journal:  Nat Rev Drug Discov       Date:  2021-05-11       Impact factor: 84.694

Review 2.  Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis.

Authors:  Martina B Lorey; Katariina Öörni; Petri T Kovanen
Journal:  Front Cardiovasc Med       Date:  2022-03-03

3.  Coronary artery disease: 'gout' in the artery?

Authors:  Timo E Strandberg; Petri T Kovanen
Journal:  Eur Heart J       Date:  2021-07-21       Impact factor: 29.983
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.